Text

Kemoradiotherapy Konkuren dengan Regimen Karboplatin + Etoposid pada Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil Stage Lanjut di Rumah Sakit Persahabatan.

---

Response rate of regiment carboplatin plus etoposide for non-small cell lung cancer is inferior than regiment used new agent as paclitaxel, docetaxel or gemcitabine. On the other hand, the combination response of chemoradiotherapy could efficacy for non-small cell lunf cancer However, there is still controvers about the toxixities if full dosed chemotheapy is used in concurrent chemoradiotherapy. This study was undertaken to evaluate the efficacy and toxicity of concurrent chemoradiotherapy in advanced stage non-small cell lung cancer patients. We conducted a retrospective study to evaluate the efficacy and toxicity of concurrent chemoradiation therapy in advanced stage non-small cell lung cancer patients trated between January 2000 and June 2005 at Persahabatan Hospital, Jakarta Indonesia. We retrospectively reviewed the medical records of 253 of 1350 advanced stage non-small cell lung cancer patients who had undergone chemoradiotherapy. In this study, the outcome of 48 patients received concurrent chemoradiotherapy with three. In this study, the outcome of 48 patients who received concurent chemoradiotherapy with three weekly regimen AUC-5 Carboplatin day 1 plus 100 mg/m2 Etoposide day 1-3 and thoracic radiotherapy 200 cGy per day for range, 50-60 Gy were analyzed. Data have shown overall respons rate was 77,1%. It was divided in categories of response objective that its were complete response in 4 of 48 (8,3%), partial response in 33 of (69,8%), stable disease 10 of 48 (20,8%) and progressive disease in olnly 1 of 48 (2.1%) patients. Time to progressive was 6-12 weeks. In this study 43 of 48 (89,5%) patients received secondline chemotherapy after progressive. The 1-years, 2-years and 3-years survival rate were 100%, 75% and 14,6%, but zero percent for 4-years survival rate. Median survival rate was 24 months (range 15-44 months) We have found mld but no grade 3 or 4 hematology toxicities. Used regimen carboplatin plus etoposide in concurrent chemotherapy setting show the high efectivity with management to toxicities.

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

Jurnal Respirologi Indonesia, 28(2): 81-87

Penerbit

Jakarta : Perhimpunan Dokter Paru Indonesia., 2008

Deskripsi Fisik

7p.

Bahasa

ISBN/ISSN

0853-7704

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

adenocarcinoma
lung neoplasms
GLUTAMATES-toxicity

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar